ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026
A murine model of amyloid-enhanced tauopathy: Comparison of wild-type and P301L-tau.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A murine model of amyloid enhanced tauopathy: progressive changes in tau pathology and behavior.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionTo optimize a model of amyloid-enhanced tauopathy we compared wild-type (WT) tau with P301L-tau in a mouse with mature amyloid.
methodsMice transgenic for amyloid precursor protein and presenilin-1 (APP+PS1, A/P) were injected intravenously with adeno-associated virus with capsid B10 (AAV.CAP-B10) expressing either WT or P301L human tau. Mice were behaviorally assessed 5 and 8 months and tissue collected 9 months after injection.
resultsA/P+WT and A/P+P301L groups were equivalently impaired in spatial learning and memory. A/P+WT mice had significantly greater tau hyperphosphorylation than A/P+P301L mice. However, A/P+P301L mice had greater deposition of phospho-tau and formation of Gallyas-positive neurofibrillary tangles (NFTs). DISCUSSION: These data demonstrate that WT-tau is more highly phosphorylated than P301L-tau in the presence of amyloid in mouse brain. Furthermore, despite the lack of NFT pathology in A/P+WT mice, WT-tau still caused cognitive impairment. The use of WT-tau in this model may make it more translatable for pre-clinical assessments of potential therapeutics for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.